US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 17:49:41 Source:styleViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:French sports minister calls for sanctions after Monaco player tapes over anti
Next:Socialite Jasmine Hartin enjoys beach snuggle with electrician hunk
You may also like
- Ben Whishaw lights up the Croisette as he joins his co
- UN suspends aid movements at night in Gaza
- Ministers announce advisory group for fast
- Progress in Gaza truce talks in Cairo, Egypt's Al Qahera news says
- Trump accepts a VP debate but wants it on Fox News. Harris has already said yes to CBS
- How to make sure your leftovers are safe to eat
- Tourism in Brazil up 7.8% in 2023
- Grief and anger in Moscow following concert attack
- Celebrity birthdays for the week of May 26